Expert NetworkExpert InterviewTEVA

Slingshot members are talking to an expert! The topic is:

Discussing the phase 2b RELIEVE UCCD study of Teva's anti-TL1A antibody, duvakitug, in ulcerative colitis and Crohn’s disease

Executed on:Feb 4, 2025 5:30 PM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: Northwestern University
  • Professor of Medicine and Medical Director of Digestive Health Center at Northwestern University
  • Treats more than 1000 patient per year for ulcerative colitis or Crohn’s diseas
  • Internationally recognized as an expert on IBD and has been an advisor on the development on multiple IBD drugs

Interview Goal

On this call we will be discussing the potential of Sanofi and Teva Pharmaceuticals'  anti-TL1A antibody (TEV-48574 aka duvakitug) in development for ulcerative colitis and Crohn’s disease and the recent results from the phase 2b RELIEVE UCCD study.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.